The search for weight loss therapies is as old as medicine itself. Small molecule treatments are marginally effective or cause undesirable side effects, some of which may be serious. Unigene Laboratories, a Boonton, New Jersey-based biopharmaceutical company, has reported on a novel approach to hunger suppression based on naturally occurring peptides.
Scientists from Unigene Laboratories presented animal data on a new molecule, UGL269, at the Keystone Symposium Conference, “Obesity: Novel Aspects of the Regulation of Body Weight,” held in Alberta, Canada on January 22. Designed by Unigene researchers, patent-pending UGL269 is an analog of a natural peptide hormone.
In their presentation, investigators described an experiment comparing UGL269 with an analog of PYY and placebo in dogs. PYY is a pancreatic peptide which, based on animal studies, is believed to suppress appetite. UGL269 and PYY were formulated identically. Both contained an absorption enhancer and a protease inhibitor to limit digestion of the peptides in the digestive tract. The placebo contained all the excipients except for the peptides.
Dogs were monitored for food intake before, during, and after the dosing period. At equivalent doses, UGL269 significantly decreased food intake throughout the treatment period of one week, while PYY exhibited a smaller effect. The food intake of dogs given a placebo remained unchanged. Dogs receiving UGL269 also showed a small but significant weight reduction whereas dogs receiving the same dose of PYY experienced barely noticeable weight loss. Both food and water intake returned to pre-dose levels during the one week washout period following the dosing period. Dogs given placebo capsules exhibited a slight increase in both food intake and weight.
“Therapies that modify feeding behavior and result in weight loss represent a significant unmet medical need,” commented Dr. Warren Levy, President and CEO of Unigene. “UGL269 may offer a new, orally administered approach for weight loss through appetite reduction.”
Obesity has reached epidemic proportions in developed countries, and in the United States in particular. Data from the Centers for Disease Control and Prevention suggest that the prevalence of people who are overweight has risen in the U.S. from the 10-13% range in 1991 to approximately 33%, for both men and women. Obesity is a risk factor for a number of serious medical conditions, including cancer and cardiovascular disease. It is also a predisposing factor in the development of Type 2 diabetes, a condition that independently leads to diseases of the kidneys, eyes, and heart/circulatory systems to name a few. Diabetes care costs the U.S. healthcare system tens of billions of dollars per year, and the U.S. economy billions of hours in lost productivity.
Small-molecule weight loss drugs have a spotty history. Many are stimulants and one, the popular phentremine (“Phen-Fen”), caused serious heart valve problems. Other systemically-acting diet drugs appear to cross the blood-brain barrier, and have been implicated in depression and mood changes. Fat-blocking drugs cause less serious side effects (fatty stools, discharge), but since they are barely more effective than diet alone, these agents have not caught on as developers had hoped.
Peptides, by contrast, are natural molecules. ULG-269 uses only naturally-occurring amino acids. If broken down in the body these peptide building blocks will be used in the same manner as if they were ingested as food.
ULG-269 is produced in E. coli through Unigene’s patented Secrapep® manufacturing technology. Secrapep provides a robust, scalable production platform for numerous peptide pharmaceuticals, including salmon calcitonin, parathyroid hormone analogs and several glucose regulatory peptides.
Peptide drugs are usually administered to patients by injection instead of in pill form because the digestive system breaks these molecules down into smaller peptides and amino acids, rendering them inactive. Through Unigene’s Enteripep® oral delivery technology, peptide drugs are protected from the digestive enzymes and acids in the stomach and small intestine, and are absorbed into the system like any other drug.
“The goal for our program was to develop a novel peptide that was composed of natural building blocks and with the ability to reduce food intake in a superior manner to PYY, and ULG-269 satisfies both criteria,” comments Dr. Levy. “Further studies will determine whether we have discovered a more natural approach for reducing food intake with fewer side effects than existing approaches. We are fortunate that our manufacturing and drug delivery capabilities position us to exploit this opportunity, in the hopes of developing a reasonably priced, orally administered tablet.”
Janet Vasquez | Newswise Science News
North and South Cooperation to Combat Tuberculosis
22.03.2018 | Universität Zürich
Researchers Discover New Anti-Cancer Protein
22.03.2018 | Universität Basel
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
22.03.2018 | Trade Fair News
22.03.2018 | Earth Sciences
22.03.2018 | Earth Sciences